【参考文献】
1.Chen et al. J Epidemiol Glob Health 13, 725–739 (2023).
2.Trends and projections of inflammatory bowel disease at the global reaional and national evels, 1990-2050: a bayesian age-period-cohort modeling study-PMC.
3.Vermeire, Severine et al. Lancet (London, England) vol. 389,10066 (2017): 266-275.doi:10.1016/S0140-6736(16)32537-5.
4.Muzammil MA , Fariha FNU , Patel T，et al. Cureus. 2023 Jun 28;15(6):e41120. doi: 10.7759/cureus.41120
5.National institutes of Heath: Clinicaltrials.gov. A study of the efficacy and safety of guselkumab in participants with moderately to severely active Crohn's disease (GALAXl.ldentifierNCT03466411. Available at: https://clinicaltrials.gov/study/NCT03466411. Accessed July 2025.
6.Clinicaltrials.gov. A Study of Gusekumab in Participants With Moderately to Severely Active Ulcerative Coltis (QUASAR).ldentifier: NCT04033445. Accessd July 2025
https://classic.clinicaltrials.gov/ct2/show/NCTO40334458
7.One-Year Efficacy of Guselkumab Versus Advanced Therapies for the Treatment of Moderately to Severely Active Crohn's Disease: A Network Meta-Analysis -PMG
